Encoded Therapeutics closed a $275 million Series F on September 9 to advance genetic medicines for neurological disorders. Its lead program, ETX101, is an experimental treatment for children with SCN1A-positive Dravet syndrome, a severe epilepsy linked to a faulty copy of a gene needed for normal brain activity.
The company is trying to change the underlying biology rather than only suppress seizures. In this form of Dravet, reduced production of a sodium-channel protein affects neurons that normally restrain electrical activity. ETX101 is designed to increase expression from the working SCN1A gene in those inhibitory neurons. Whether that produces durable clinical benefit remains a question for trials.
Delivery is an important part of the product. The treatment uses a modified viral carrier to transport genetic instructions and is administered through an infusion into the brain's fluid-filled ventricles. Encoded intends it as a one-time intervention, not a medicine taken each day. That describes the development goal and route, not an assurance of lifelong benefit or an approved treatment option.
Encoded also develops and manufactures its candidates internally. The new program of work includes a pivotal study in infants and young children and an expansion study in older children and adolescents. This means the business must produce a consistent investigational medicine while collecting evidence across patients—not merely demonstrate a laboratory mechanism.
GV and an unnamed healthcare fund co-led the financing, with participation from investors including ARCH Venture Partners and RTW Investments. Encoded says proceeds will support ETX101 studies, manufacturing scale-up and work toward a 2027 regulatory application to begin testing ETX301 for post-amputation neuroma pain. Fierce Biotech independently reported the round.
The company has reported encouraging interim findings, but pivotal development must establish the treatment's benefits and risks more convincingly. A central issue is whether seizure improvements are accompanied by meaningful developmental gains. Building manufacturing capacity helps prepare for that next stage; it does not itself mean the medicine has been approved or is commercially available.